The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. (2nd November 2022)

• Record Type: Journal Article
• Authors: Taurelli Salimbeni, Beatrice; Corvaja, Carla; Valenza, Carmine; Zagami, Paola; Curigliano, Giuseppe
• Is Part Of: Expert opinion on investigational drugs. Volume 31:Number 11(2022)
• Page Start: 1203
• Page End: 1226
• Publication Date: 2022-11-02
• Subjects: combined treatments -- failed clinical trials -- targeted therapy -- triple-negative breast cancer; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2022.2151433
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction: Triple-negative breast cancer (TNBC) accounts for 15–20% of breast cancers (BC) and has the worst prognosis. It is characterized by the absence of both hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2). TNBC has more limited therapeutic options compared to other subtypes, meaning that there is still a long way to go to discover target treatments. Areas covered: Our review aims to summarize phase II/III clinical trials enrolling patients with TNBC that have been published between 2017 and 2022 but failed to reach their primary endpoint. We here try to emphasize the limitations and weaknesses noted in negative studies and to point out unexpected results which might be useful to enhance the therapeutic approach to TNBC disease. Expert opinion: A deeper understanding of the mechanisms behind TNBC heterogeneity allowed to enhance the knowledge of new prognostic and predictive biomarkers of response. However, it is also through several failed clinical trials that we were able to define new therapeutic approaches which improved TNBC patients' clinical outcomes. Nowadays, we still need to overcome several difficulties to fully recognize different intracellular and extracellular pathways that crosstalk in TNBC and the mechanisms of resistance to identify novel tailored-patients' therapies.